微创与开放胰腺切除术治疗胰腺神经内分泌肿瘤:四机构10年1023例经验
该多机构回顾性研究对比2009-2019年间1023例胰腺神经内分泌肿瘤(PNET)患者行微创(447例)与开放(576例)胰腺切除术的围手术期结局。微创胰十二指肠切除术失血量更少、临床相关术后胰瘘(CR-POPF)率更低,微创远端胰腺切除术住院更短,但微创中段胰腺切除术CR-POPF率更高;调整病理差异后,微创与开放手术的无复发生存和总生存相当。
要点
- 微创胰十二指肠切除治疗PNET的失血量(150 vs 400 mL)和CR-POPF率(13% vs 27%)均优于开放手术。
- 微创远端胰腺切除的住院时间更短(5 vs 6天),CR-POPF率与开放相当。
- 微创中段胰腺切除的CR-POPF率高于开放(45% vs 15%),需谨慎选择。
核心结论
- 微创胰腺切除术治疗PNET的结局优于或相当于开放手术。
- 调整病理差异后,微创与开放手术的无复发生存和总生存相当。
研究设计与样本
- 多机构回顾性队列研究,纳入2009-2019年间4家机构的1023例PNET胰腺切除术患者。
- 微创组447例(其中机器人230例、腹腔镜217例),开放组576例。
- 比较两组临床病理数据和围手术期结局。
主要发现
- 全组男性51%,平均年龄58岁,中位肿瘤大小2.1 cm,73%为1级PNET。
- 手术方式:胰十二指肠切除318例(31%),远端胰腺切除541例(53%),剜除80例(7.8%),中段胰腺切除72例(7%),全胰腺切除12例(1.2%)。
- 微创胰十二指肠切除较开放手术失血量显著更低(150 vs 400 mL,p<0.001),CR-POPF率更低(13% vs 27%,p=0.030)。
- 微创远端胰腺切除较开放手术住院时间更短(5 vs 6天,p<0.001)。
- 微创中段胰腺切除的CR-POPF率高于开放手术(45% vs 15%,p=0.013)。
关键数值与推荐
- 微创胰十二指肠切除:失血量150 vs 400 mL(p<0.001),CR-POPF率13% vs 27%(p=0.030)。
- 微创远端胰腺切除:住院时间5 vs 6天(p<0.001)。
- 微创中段胰腺切除:CR-POPF率45% vs 15%(p=0.013)。
临床怎么用
- 对于PNET,微创胰十二指肠切除和远端胰腺切除可考虑作为开放手术的替代选择。
- 微创中段胰腺切除需警惕较高的CR-POPF风险,应个体化决策。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 未报告长期肿瘤学结局的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resection of pancreatic neuroendocrine tumors (PNETs) may be associated with adverse perioperative outcomes compared with pancreatic adenocarcinoma given the high-risk nature of soft glands with small pancreatic ducts. The effect of minimally invasive surgery (MIS) pancreatectomy on outcomes of PNETs remains to be examined, which is the aim of this study. STUDY DESIGN: Between 2009 and 2019, 1,023 patients underwent pancreatectomy for PNETs at 4 institutions. Clinicopathologic data and perioperative outcomes of patients who underwent MIS (n = 447) and open resections (n = 576) were compared. RESULTS: Of the 1,023 patients, 51% were male, the mean age was 58, the median tumor size was 2.1 cm, and 73% were grade 1 PNETs. There were 318 (31%) pancreatoduodenectomies (PDs), 541 (53%) distal pancreatectomies (DPs), 80 (7.8%) enucleation (ENs), 72 (7%) central pancreatectomies (CPs), and 12 (1.2%) total pancreatectomies. Almost half of the patients (N = 447, 44%) had MIS operations, of which 230 (51%) were robotic and 217 (49%) were laparoscopic. Compared with open operations, MIS PDs had significantly lower operative blood loss (150 vs 400 mL, p < 0.001) and rate of clinically relevant postoperative pancreatic fistulas (CR-POPFs; 13% vs 27%, p = 0.030), and MIS DPs had a shorter length of stay (5 vs 6 days, p < 0.001). Although MIS DPs and ENs had CR-POPFs comparable with open operations, MIS CPs had a higher CR-POPF rate (45% vs 15%, p = 0.013). After adjusting for pathological differences, MIS pancreatectomy was associated with recurrence-free survival and overall survival comparable with open pancreatectomy. CONCLUSIONS: MIS pancreatectomy for PNETs is associated with improved outcomes or outcomes comparable with open resection.
引用
- Zheng J, Pulvirenti A, Javed AA, et al. Minimally Invasive vs Open Pancreatectomy for Pancreatic Neuroendocrine Tumors: Multi-Institutional 10-Year Experience of 1,023 Patients. J Am Coll Surg. 2022. PMID: 35839409. doi:10.1097/XCS.0000000000000257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。